Abbott Diagnostics is sponsoring a workshop as part of the scientific programme at Focus 2009, to be held 18-21 May in Liverpool.
The session 'Advancing Patient Management with Novel Diagnostic Markers' (to be held 19 May) will discuss how innovative new markers can impact on unmet clinical needs.
A prime example is the introduction of neutrophil gelatinase-associated lipocalin (NGAL) for assessing patients at risk of acute kidney injury.
The workshop will also review the opportunities and hurdles presented by implementation of novel markers in the UK healthcare system.
Abbott's commitment to scientific advancement has driven the development of a number of new novel markers, including uNGAL, ProGRP (lung cancer differentiation), MPO (cardiac) and HE4 (ovarian cancer).
Abbott will also host a Forum Interactive session at Focus 2009, on 21 May, discussing how the right IT components can enhance efficiencies and add extra functionality to modern laboratories.
In particular, this will focus on the role of hardware virtualisation in the future delivery of laboratory medicine.
